Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850028 | 0.81 | RIPK1 (0.49) | KMT2AMAPTGAAKDM4EMEN1 | |
| SCHEMBL919800 | 0.78 | F2 (0.48) | PPARAKMT2AGAAMMP1MMP2 | |
| SCHEMBL919039 | 0.75 | KMT2A (0.46) | KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL918991 | 0.75 | MAPK14 (0.50) | MAPTMMP1MMP2MMP13EPHX2 | |
| SCHEMBL919807 | 0.74 | CYP2C19 (0.47) | PPARAKMT2AGAAEPHX2NPC1 | |
| SCHEMBL919163 | 0.74 | SCN9A (0.47) | GAAMMP1MMP2MMP13EPHX2 | |
| SCHEMBL919803 | 0.74 | MEN1 (0.43) | KMT2AMAPTGAAKDM4ENPC1 | |
| SCHEMBL920846 | 0.73 | MAPK14 (0.47) | MMP1MMP2MMP13 | |
| SCHEMBL920177 | 0.73 | SCN3A (0.65) | — | |
| SCHEMBL3971356 | 0.72 | SLC6A4 (0.47) | PPARAKMT2APPARGKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| EP-1032377-A4 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2006-06-14 | — | — | EP | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-7872127-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2201945-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026614-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | PPARA 1579/4885KMT2A 671/4885MAPT 1562/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | PPARA 1421/4885KMT2A 4185/4885MAPT 1779/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | PPARA 1913/4885KMT2A 662/4885MAPT 478/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | PPARA 1575/4885KMT2A 845/4885MAPT 2392/4885 |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | PPARA 1579/4885KMT2A 671/4885MAPT 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.